Clinical trials: Stem Cell Mobilization
Sickle Cell Disease
Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)
Hematopoietic stem cell (HSC)-based gene therapies now offer curative potential for patients with sickle cell disease (SCD), with decreased toxicity compared to allogeneic hematopoietic cell transplantation.
- Trial name
- NCT05618301
- Testing
- Motixafortide, Natalizumab, Leukapheresis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Chronic Myeloproliferative Disorders
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Myelofibrosis
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00006367
- Testing
- filgrastim, busulfan, cytarabine
- Where
- 9 sites in United States, France and 1 more
- Sponsor
- Fred Hutchinson Cancer Center
Bone Marrow / Autologous Transplants
Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation
The aim of this registry is to provide information, in day-to-day practice, on Plerixafor prescription modalities in France, over a 13-month period in order to address the health authorities' request.
- Trial name
- NCT01738373
- Testing
- Plerixafor
- Where
- France
- Volunteers
- 262 people
- Sponsor
- Genzyme, a Sanofi Company
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
This phase II trial studies how well fludarabine phosphate, cyclophosphamide, total body irradiation, and donor stem cell transplant work in treating patients with blood cancer.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT03333486
- Testing
- Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Roswell Park Cancer Institute
Diffuse Large Cell Lymphoma Relapsed/Refractory
Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
The goal of this clinical trial is to show that incorporating ofatumumab instead of rituximab in combination with etoposide and cytarabine (OVA) is successful in collecting autologous stem cells for use in an autologous stem cell…
- Trial name
- NCT01555541
- Testing
- Ofatumumab, Etoposide, Cytarabine
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- C. Babis Andreadis
Hematologic Malignancies
Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy
No prospective randomized trials have evaluated the most efficacious dose of cyclophosphamide to mobilize autologous stem cells.
- Trial name
- NCT02139280
- Testing
- Cyclophosphamide
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma
RATIONALE: There are different methods of stem cell mobilization, such as using colony-stimulating factors alone or following chemotherapy priming.
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT01074060
- Testing
- plerixafor, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
Fanconi Anemia
Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and Plerixafor
The purpose of this study is to assess the feasibility of Plerixafor used in combination with G-CSF (Granulocyte Colony Stimulating Factor) in 5 Fanconi anemia patients to mobilize and collect a sufficient number of peripheral…
- Trial name
- FancoMob (NCT02678533)
- Testing
- G-CSF, Plerixafor
- Where
- France
- Volunteers
- 4 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
End-stage Kidney Disease, Diabetes Mellitus
Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula
Background Arteriovenous (AV) fistula is the most common vascular access for long-term hemodialysis in the end-stage renal disease (ESRD) patients. About 25% of these patients are diabetes mellitus.
- Conditions
- End-stage Kidney Disease, Diabetes Mellitus, Arteriovenous Fistula
- Trial name
- NCT01863914
- Testing
- Rosuvastatin
- Where
- Taiwan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Cheng-Kung University Hospital
Diabetes Mellitus
Bone Marrow Progenitor Cell Mobilization in Diabetes
Diabetes mellitus is associated with a significant reduction of circulating progenitor cells (CPCs). These include endothelial progenitor cells (EPCs), which are involved in cardiovascular homeostasis and repair.
- Trial name
- GCSF-DM (NCT01102699)
- Testing
- Filgrastim, hrG-CSF
- Where
- Italy
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of Padova
Hematologic Malignancies, Acute Myeloid Leukemia
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
This study is a Phase 1, non-randomized, open-label/Phase 2 randomized, blinded study of ProTmune (ex vivo programmed mobilized peripheral blood cells) versus non-programmed mobilized peripheral blood cells for allogeneic…
- Conditions
- Hematologic Malignancies, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT02743351
- Testing
- ProTmune, Control Arm
- Where
- 15 sites in United States
- Volunteers
- 96 people
- Sponsor
- Fate Therapeutics
Non-Hodgkin's Lymphoma, Multiple Myeloma
Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation
This protocol will investigate the effectiveness of plerixafor in the up-front setting in avoiding a second round of mobilization and whether this translates into a clinical and economic benefit.
- Trial name
- NCT01339572
- Testing
- Plerixafor, Filgrastim
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Florida
Multiple Myeloma
Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
This is a randomized, double-blinded, placebo-controlled, multi-center phase Ⅲ bridging clinical study designed to evaluate the efficacy, safety, and pharmacokinetic and pharmacodynamic profiles of Motixafortide (BL-8040) + G-CSF…
- Trial name
- NCT06514508
- Testing
- Motixafortide+G-CSF
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
Healthy
Safety and Efficacy of POL6326 for Mobilization of Hematopoietic Stem Cells in Healthy Volunteers
Phase I study to determine and compare the safety/tolerability of single ascending doses of POL6326 by intravenous infusion.
- Trial name
- NCT01841476
- Testing
- POL6326
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Polyphor Ltd.
Exercise-Induced Circulating Progenitor Cell Mobilization
Exercise Intensity and Circulating CD34+ Progenitor Cell Mobilization in Trained Adults
This randomized crossover study investigated whether exercise intensity influences the mobilization of circulating CD34+ progenitor cells when total external work is matched.
- Trial name
- NCT07841561
- Testing
- Higher-Intensity Work-Matched Cycling Exercise, Lower-Intensity Work-Matched Cycling Exercise
- Where
- Iraq
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Samarra University
Multiple Myeloma
Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects
This is a multicenter, randomized, open label study designed to compare the efficacy and safety of lenalidomide with low-dose alkylating agents versus high-dose melphalan followed by stem cell support in newly diagnosed…
- Trial name
- NCT01091831
- Testing
- Cyclophosphamide, Lenalidomide, Dexamethasone
- Where
- Italy
- Volunteers
- 389 people
- Sponsor
- Fondazione EMN Italy Onlus
End Stage Liver DIsease
Mobilization of Stem Cells With G-CSF and Mozobil in Patients With End Stage Liver Disease
A phase I trial to study the safety of mobilization of stem cells with G-CSF and Mozobil in patients with chronic liver disease.
- Trial name
- NCT01711073
- Testing
- Mobilization with G-CSF and Mozobil
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Proteonomix, Inc.
Beta-Thalassemia
Evaluating the Safety of G-CSF Mobilization in Individuals With Beta Thalassemia Major
Beta thalassemia major is a serious genetic disease of the blood. Treatments are limited, and although a bone marrow transplant from a compatible donor can be curative, only a limited percentage of individuals with this disease…
- Trial name
- NCT00336362
- Testing
- Hydroxyurea
- Where
- Greece
- Volunteers
- 26 people
- Sponsor
- University of Washington
Congenital Hemolytic Anemia, Sickle Cell Disease
Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias
People with severe congenital anemias, such as sickle cell anemia and beta-thalassemia, have been cured with bone marrow transplantation (BMT).
- Trial name
- NCT00061568
- Testing
- Peripheral blood hematopoietic progenitor cell (PBPC) transplant, Alemtuzumab, Peripheral blood hematopoietic progenitor cell Apheresis
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Multiple Myeloma
High-dose Chemotherapy+G-CSF in Peripheral Blood Stem Cell Mobilization in Patients With Multiple Myeloma
This study was a multi-center, randomized, prospective study. The purpose is to clarify that high-dose VP-16+G-CSF has better mobilization efficiency and less toxic and side effects compared with high-dose CTX+G-CSF, and minimize…
- Trial name
- NCT05517213
- Testing
- Etoposide, Cyclophosphamide
- Where
- China
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences